This is an update on Biosensors Stock: Management has been buying up Biosensors stocks while Biosensors stocks reach the current low price level at around $0.84; this is around 30% discount to the $1.20 prices that Biosensors stock has been trading before the stock heads south. Biosensors’ products are in stents and other cardiac devices with its key market in US, Japan and China. The company has not been doing well in stock prices though I believe that the company will still look for Mergers & Acquisitions targets as it has an excellent cash flow. Can you guess how much is the cash flow? As of the previous Annual Report of Biosensors stock, the cash flow is US$600 million! The founder and Chairman of Biosensors is no longer a substantial shareholder of the company but it looks pretty much he is quite involved in plans to grow the ......
